Anthem Biosciences Ltd
ANTHEM
Company Profile
Business description
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
Contact
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1
Bommasandra
BangaloreKA560 099
INDT: +91 8066724000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,324.60 | 40.80 | 0.44% |
| CAC 40 | 8,201.98 | 27.78 | 0.34% |
| DAX 40 | 24,226.46 | 395.47 | 1.66% |
| Dow JONES (US) | 46,469.36 | 278.75 | 0.60% |
| FTSE 100 | 9,405.20 | 50.63 | 0.54% |
| HKSE | 25,858.83 | 611.73 | 2.42% |
| NASDAQ | 22,915.18 | 235.21 | 1.04% |
| Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
| NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
| S&P 500 | 6,715.45 | 51.44 | 0.77% |
| S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
| SSE Composite Index | 3,863.89 | 24.14 | 0.63% |